VOTRIENT
Votrient (Pazopanib) Overview
Votrient, containing the active ingredient Pazopanib, is a targeted therapy used primarily for the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma. It works by inhibiting the action of specific proteins that promote cancer cell growth and blood vessel formation.
Indications
Votrient is prescribed for patients with:
- Advanced renal cell carcinoma
- Soft tissue sarcoma after prior chemotherapy
Mechanism of Action
Pazopanib is a multi-kinase inhibitor that targets various receptors involved in tumor growth and angiogenesis, including VEGFR, PDGFR, and c-KIT. By blocking these pathways, Votrient helps to slow down or stop the spread of cancer cells.
Dosage and Administration
The recommended dosage of Votrient is determined by a healthcare professional based on individual patient needs. It is typically taken once daily on an empty stomach, either one hour before or two hours after a meal.
Side Effects
Common side effects of Votrient may include:
- Nausea
- Fatigue
- Diarrhea
- Hypertension
- Loss of appetite
Patients should report any severe or persistent side effects to their healthcare provider.
Warnings and Precautions
Before starting Votrient, patients should inform their doctor of any pre-existing conditions, especially:
- Liver problems
- Heart disease
- High blood pressure
Regular monitoring of liver function and blood pressure is advised during treatment.
Drug Interactions
Votrient may interact with other medications. Patients should provide a complete list of all medications, supplements, and herbal products they are taking to their healthcare provider to avoid potential interactions.
Conclusion
Votrient (Pazopanib) offers an effective treatment option for advanced kidney cancer and certain types of sarcoma. As with any medication, it is essential to follow the prescribed treatment plan and maintain open communication with healthcare providers to manage any side effects or concerns.
